Nasdaq GlobeNewswire

Accellion Announces New Partner Program to Address File Sharing Security and Governance Challenges


Regulatory Compliance and Risk Mitigation Against Data Breaches are Key Drivers

PALO ALTO, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Accellion, Inc., the leading platform that enables organizations to securely share sensitive information with the outside world while maintaining the controls and visibility needed to demonstrate compliance, today announced a new partner program.

The program's aim is to identify and collaborate with leading resellers and independent software vendors (ISVs) that are closely aligned with Accellion's focus on protecting sensitive information to minimize risk and demonstrate compliance.

Accellion recognizes the tremendous value partners provide in connecting organizations to technology solutions that best meet their needs. When the solution addresses an enterprise-wide challenge like securing sensitive information or demonstrating compliance with regulations like GDPR, that value is enhanced. 

"Accellion sees a new reality for enterprises, namely more data, more risk, and more oversight," commented Laureen Smith, Vice President, Worldwide Business Development for Accellion. "With kiteworks, we have a unique opportunity to support partners in helping their customers protect their most valuable digital assets. We look forward to developing long-term, growth-oriented relationships with partners who share this vision."

Accellion is currently developing a robust network of partners that are focused on security, particularly in highly regulated industries like healthcare, financial services and government. For partners who share Accellion's commitment to enhancing an organization's security and compliance posture, Accellion offers an innovative margin program that exceeds industry norms and market development funds (MDFs).

"We view partners as a crucial extension of our sales efforts, particularly in Europe and the Middle East," said Harry Zorn, Vice President of EMEA Sales for Accellion. "By expanding our existing partner network, we are able to extend our reach into new markets and help more customers send sensitive information securely. We look forward to working with additional partners to identify new business opportunities and accelerate our revenue growth." 

Accellion is already forging strong relationships with partners who have a successful track record of addressing complex cybersecurity challenges for their customers. With cyber attacks increasing in frequency and severity, followed by tightening regulations and rising fines for compliance violations, organizations will continue to look to their partners for a solution.

Accellion will be announcing subsequent partnerships in the coming months.

To learn more about Accellion, please email or visit:

Accellion, Inc. enables enterprise organizations to securely connect all their content to the people and systems that are part of their critical business processes, regardless of the applications that create that content or where it is stored, while maintaining the controls and visibility needed to demonstrate compliance. Accellion's solutions have been used by more than 25 million users and over 3,000 of the world's leading corporations and government agencies including NYC Health + Hospitals; KPMG; Kaiser Permanente; Latham & Watkins; National Park Service; Umpqua Bank; Cargill; and the National Institute for Standards and Technology (NIST). For more information please visit or call (650) 485-4300. Follow Accellion's BlogTwitter and LinkedIn.

Media contact

Rachel Kaseroff
RJK Communications
(415) 341-5625

Accellion and kiteworks are registered trademarks of Accellion, Inc. in the US and other countries. All other trademarks contained herein are the property of their respective owners.

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Accellion via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

New Elemica Trace Solution Delivers Shipment Risk Analysis for Digital Transformation19.3.2018 13:09Pressemelding

Real-Time Information Matched with GPS Locations Provides Accurate Delivery Information WAYNE, Pa., March 19, 2018 (GLOBE NEWSWIRE) -- Elemica, the leading Digital Supply Network for process manufacturing industries, introduces Elemica Trace, a solution that provides real-time shipment and risk visibility to customer service, transport planners, and supply chain managers, allowing them to monitor and proactively manage the movement of products to customers and inbound to manufacturing centers. "Shipment disruptions occur and teams can spend hours manually tracking down what is happening. What's worse, sometimes your customer complaint is the first indication you have of a late shipment," said Rich Katz, CTO of Elemica. "Trace eliminates the time and stress of tracking shipments and enables your teams to increase the positive interactions with your customers." Elemica Trace uses shipment data, carrier signals, a geo-location interface, and predictive algorithms to identify shipments in

Resverlogix Exceeds Full Enrollment for the Pivotal Phase 3 BETonMACE Clinical Trial19.3.2018 12:00Pressemelding

The BETonMACE trial has now surpassed 2,400 enrolled patients and topline data is expected around the end of 2018 CALGARY, Alberta, March 19, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has successfully surpassed the planned enrollment target of over 2,400 patients in the ongoing Phase 3 BETonMACE trial. The trial's first patient was enrolled on November 11th, 2015. The goal of the trial is to confirm the effect of Resverlogix' lead drug, apabetalone, in Cardiovascular Disease (CVD) patients with type 2 Diabetes Mellitus (DM) and low high-density lipoproteins (HDL). The primary endpoint of the BETonMACE trial is designed to establish a relative risk reduction (RRR) of Major Adverse Cardiac Events (MACE), narrowly defined as a single composite endpoint of cardiovascular death, non-fatal myocardial infarction (MI) and stroke. Secondary pre-specified endpoints in the trial will also examine renal function and MACE in patien

SolarWinds Places Highest on the Ability to Execute Axis in 2018 Gartner Magic Quadrant for Network Performance Monitoring and Diagnostics19.3.2018 11:30Pressemelding

AUSTIN, Texas, March 19, 2018 (GLOBE NEWSWIRE) -- SolarWinds, a leading provider of powerful and affordable IT management software, placed highest on the ability to execute axis in the 2018 Gartner Magic Quadrant for Network Performance Monitoring and Diagnostics1. This Gartner report evaluated 22 suppliers of Network Performance Monitoring and Diagnostics products. The firm's evaluation criteria for ability to execute included the following: product or service, overall viability, sales execution and pricing, market responsiveness and record, marketing execution, customer experience, and operations. Of all the vendors evaluated in the report, SolarWinds placed highest on the ability to execute axis. "For three years in a row, Gartner has positioned us as highest on the ability to execute axis in the Magic Quadrant for Network Performance Monitoring and Diagnostics. In our view, this result confirms our commitment to helping our customers manage their network operations with a powerful

Record High Number of Toll Transactions Cleared in Ireland in 201719.3.2018 10:51Pressemelding

ISSY LES MOULINEAUX, France, March 19, 2018 (GLOBE NEWSWIRE) -- The number of transactions processed through emovis's toll interoperability cloud-based hub in Ireland has reached a record high with over 50 million transactions cleared in 2017. Thanks to its toll interoperability solution, emovis is contributing to the improved mobility of millions of Irish drivers, by allowing them to travel seamlessly with just one toll tag across the whole country. As of January 2018, over 650,000 toll transponders are in use. With this new success, emovis demonstrates its leadership in designing and operating innovative mobility solutions that offer the best levels of service for road users in Ireland and throughout the world. About emovis was awarded the contract for managing Ireland's toll interoperability hub by the National Roads Authority (now Transport Infrastructure Ireland) in June 2013 following a competitive tender. As part of this contract, emovis designed, developed and is curre

Phenom People Set to Attend UNLEASH London19.3.2018 09:00Pressemelding

Candidate Experience Software Pioneer Attends UK Conference HORSHAM, Pa., March 19, 2018 (GLOBE NEWSWIRE) -- Phenom People, the leader in Talent Relationship Marketing (TRM), announced today that it will attend UNLEASH Conference & Expo on March 20-21 at the ExCel London. "We are no stranger to UNLEASH's strong turnout of highly passionate and forward-thinking individuals who are ready for the next big thing in technology. The inspiration and exchange of new ideas from the world's greatest thought leaders UNLEASH draws in every year, is what we look forward to the most," said Mahe Bayireddi CEO at Phenom People. "Our presence at this year's UNLEASH is vitally important as we continue to emerge as a global TRM leader with a growing list of European clients." UNLEASH, formerly HR Tech World, is held around the globe and was created to enhance the Future of Work by marrying technology with efficient business practices. UNLEASH London's speaker line-up consists of many big-league names inc

Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights16.3.2018 22:32Pressemelding

Investor Conference Call on Tuesday, March 27th at 10:00 am ET NEW YORK and CLEVELAND, March 16, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced financial results for the fourth quarter. The Company will host a call to update investors on recent clinical developments and year-end financial results on Tuesday, March 27th at 10:00 am (Eastern). Interested parties are invited to participate in the call by dialing 877-407-9210 (toll free domestic) or 201-689-8049 (International). "The past year was marked by several defining events in the company's history, having advanced our two lead clinical programs, EB-101 in Epidermolysis Bullosa and ABO-102 in MPS IIIA, and initiated our third clinical program, ABO-101 in MPS IIIB. The strong safety and biopotency data observed in our three active clinical trials and the s

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom